Zidovudine: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Zidovudine}} | {{Zidovudine}} | ||
'''''For patient information, click <u>[[Zidovudine (patient information)|here]]</u>'''''. | '''''For patient information about Zidovudine Injection, click <u>[[Zidovudine Injection (patient information)|here]]</u>'''''. | ||
'''''For patient information about Zidovudine Oral, click <u>[[Zidovudine Oral (patient information)|here]]</u>'''''. | |||
{{CMG}} | {{CMG}} | ||
Revision as of 18:09, 9 January 2014
For patient information about Zidovudine Injection, click here. For patient information about Zidovudine Oral, click here.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Zidovudine (INN) or azidothymidine (AZT) (also called ZDV) is an antiretroviral drug, the first approved for treatment of HIV. It is also sold under the names Retrovir® and Retrovis®, and as an ingredient in Combivir® andTrizivir®. It is an analog of thymidine.
Category
Antiretroviral
US Brand Names
RETROVIR®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages